6533b850fe1ef96bd12a8250
RESEARCH PRODUCT
Subcutaneous trastuzumab therapy for HER2-positive early breast cancer in the routine clinical practice: First interim analysis of the National Non-Interventional Study (NIS) HerSCin.
Andrea DistelrathSherko KümmelStella KeitelKerstin Luedtke-heckenkampMarcus SchmidtAntonia Ruf-doerdelmannSabine SchmatlochJuergen Wackersubject
OncologyCancer Researchmedicine.medical_specialtybusiness.industryInterim analysisSurgeryOncologyTrastuzumabInternal medicineNon interventionalmedicineRoutine clinical practiceskin and connective tissue diseasesbusinessmedicine.drugEarly breast cancerdescription
581Background: In 2013 a subcutaneous (SC) formulation of trastuzumab (T) was approved based on non-inferiority to intravenous (IV) T as proven in the HannaH trial. So far no data from the routine ...
year | journal | country | edition | language |
---|---|---|---|---|
2016-05-20 | Journal of Clinical Oncology |